Drug-delivering nerve conduit improves regeneration in a critical-sized gap.
Animals
Disease Models, Animal
Drug Carriers
/ administration & dosage
Glial Cell Line-Derived Neurotrophic Factor
/ administration & dosage
Mice
Peripheral Nerve Injuries
/ therapy
Polytetrafluoroethylene
/ administration & dosage
Regeneration
Regenerative Medicine
/ methods
Tacrolimus
/ administration & dosage
Tissue Scaffolds
Treatment Outcome
FK506
GDNF
drug delivery
nerve conduit
peripheral nerve injury
Journal
Biotechnology and bioengineering
ISSN: 1097-0290
Titre abrégé: Biotechnol Bioeng
Pays: United States
ID NLM: 7502021
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
22
06
2018
revised:
04
09
2018
accepted:
05
09
2018
pubmed:
20
9
2018
medline:
18
12
2019
entrez:
20
9
2018
Statut:
ppublish
Résumé
Autologous nerve grafts are the current "gold standard" for repairing large nerve gaps. However, they cause morbidity at the donor nerve site and only a limited amount of nerve can be harvested. Nerve conduits are a promising alternative to autografts and can act as guidance cues for the regenerating axons, without the need to harvest donor nerve. Separately, it has been shown that localized delivery of GDNF can enhance axon growth and motor recovery. FK506, an FDA approved small molecule, has also been shown to enhance peripheral nerve regeneration. This paper describes the design of a novel hole-based drug delivery apparatus integrated with a polytetrafluoroethylene (PTFE) nerve conduit for controlled local delivery of a protein such as GDNF or a small molecule such as FK506. The PTFE devices were tested in a diffusion chamber, and the bioactivity of the released media was evaluated by measuring neurite growth of dorsal root ganglions (DRGs) exposed to the released drugs. The drug delivering nerve guide was able to release bioactive concentrations of FK506 or GDNF. Following these tests, optimized drug releasing nerve conduits were implanted across 10 mm sciatic nerve gaps in a BL6 yellow fluorescent protein (YFP) mouse model, where they demonstrated significant improvement in muscle mass, compound muscle action potential, and axon myelination in vivo as compared with nerve conduits without the drug. The drug delivery nerve guide could release drug for extended periods of time and enhance axon growth in vitro and in vivo.
Substances chimiques
Drug Carriers
0
Glial Cell Line-Derived Neurotrophic Factor
0
Polytetrafluoroethylene
9002-84-0
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
143-154Informations de copyright
© 2018 Wiley Periodicals, Inc.